Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Tanrıverdi, Özgür

doi:10.1007/s12032-014-0384-y

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colon cancer is the third most common cancer and the fourth cause of cancer mortality globally [ 1 , 2 ]. Although the prognosis was steadily or started to increase by strategy for standard curative resection-based, multidisciplinary, and comprehensive therapy of colon cancer, the 5-year relative survival remains discouraging especially in low-income countries [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer

Jiang

Yang

et al. 2017

Disease Markers

View full text Add to dashboard Cite

Deregulation of G protein-coupled receptor kinase 3 (GRK3), which belongs to a subfamily of kinases called GRKs, acts as a promoter mechanism in some cancer types. Our study found that GRK3 was significantly overexpressed in 162 pairs of colon cancer tissues than in the matched noncancerous mucosa (P < 0.01). Based on immunohistochemistry staining of TMAs, GRK3 was dramatically stained positive in primary colon cancer (130/180, 72.22%), whereas it was detected minimally or negative in paired normal mucosa specimens (50/180, 27.78%). Overexpression of GRK3 was closely correlated with AJCC stage (P = 0.001), depth of tumor invasion (P < 0.001), lymph node involvement (P = 0.004), distant metastasis (P = 0.016), and histologic differentiation (P = 0.004). Overexpression of GRK3 is an independent prognostic indicator that correlates with poor survival in colon cancer patients. Consistent with this, downregulation of GRK3 exhibited decreased cell growth index, reduction in colony formation ability, elevated cell apoptosis rate, and impaired colon tumorigenicity in a xenograft model. Hence, a specific overexpression of GRK3 was observed in colon cancer, GRK3 potentially contributing to progression by mediating cancer cell proliferation and functions as a poor prognostic indicator in colon cancer and potentially represent a novel therapeutic target for the disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer

Jiang

Yang

et al. 2017

Disease Markers

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, there is no evidence of direct association of these factors with CIT in the earlier related studies. [10][11][12][13][14][15][16] Several studies have reported a significant association between high ferritin and chemotherapy-induced hematologic consequences. 17,18,[26][27][28] There is some evidence that iron or ferritin has suppressive effects on hematopoietic cell proliferation and differentiation.…”

Section: Discussionmentioning

confidence: 99%

“…In these studies, the main covariates included age, type of chemotherapy regimen, prior chemotherapy or surgery, platelet count, lymphocyte count, body surface area, hematocrit, albumin, bone marrow metastases, diabetes, pulmonary disease, treatment with a drug affecting platelet function, prior episode of bleeding, performance status, Helicobacter pylori infection, level of plasma D-dimer, and blood group. [10][11][12][13][14][15][16] Development of predictive models for chemotherapyinduced hematologic toxicities based on simple and cost-effective markers could have substantial clinical value. In our recent studies, some laboratory and clinical predictors of hematologic toxicities (i.e.…”

Section: Introductionmentioning

confidence: 99%

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Razzaghdoust

Mofid

Zangeneh

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Chemotherapy-induced thrombocytopenia is a serious complication in chemotherapy-treated patients. Identification of patients at risk for chemotherapy-induced thrombocytopenia could have clinical value in personalized management of patients and optimized administration of prophylactic thrombopoietic agents. The aim of this study was to develop a predictive model for chemotherapy-induced thrombocytopenia (platelet count < 100,000/µl) in cancer patients undergoing chemotherapy. Methods A total of 14 covariates were prospectively assessed as explanatory variables in a cohort of consecutive patients with solid tumors or lymphoma. A multivariable logistic regression model was developed after univariable analysis. A bootstrapping technique was applied for internal validation. Results Data from 305 patients during 1732 chemotherapy cycles were considered for analysis. Forty-eight patients (15.73%) developed chemotherapy-induced thrombocytopenia during their treatment course. The multivariable model exhibited three final predictors for chemotherapy-induced thrombocytopenia, including high ferritin (odds ratio, 4.41; bootstrap P = 0.001), estimated glomerular filtration rate <60 ml/min/1.73 m2 (odds ratio, 3.08; bootstrap P = 0.005), and body mass index <23 kg/m2 (odds ratio, 2.23; bootstrap P = 0.044). The main characteristics of the model include sensitivity 75%, specificity 65.4%, positive likelihood ratio 2.16, and negative likelihood ratio 0.382. Moreover, the model was well calibrated (Hosmer–Lemeshow P = 0.713) and the area under the receiver operating characteristic curve was 0.735 (95% confidence interval, 0.654–0.816; P < 0.001). Conclusions We developed a predictive model for chemotherapy-induced thrombocytopenia based on readily available and easily assessable clinical and laboratory factors. This study may provide a valuable insight to guide optimized treatment of cancer patients. Further studies with larger sample size are warranted.

show abstract

“…The study discovered that blood group O was a distinct risk factor for chemotherapy-induced thrombocytopenia (P=0.035, OR 3.14, 95% CI 1.16-7.01). Unlike our study, this one lacked a control group, and the majority of the patients had the O blood group, which may have affected the findings (12).…”

Section: Discussionmentioning

confidence: 83%

Relation of Immune Thrombocytopenia and Blood Group: A Retrospective Single Center Study

SELİM,

YAVAŞ,

BOLAMAN

2023

Medical Records

View full text Add to dashboard Cite

Objective: Although blood group antigens were initially identified as erythrocyte surface antigens and their significance was mainly ascribed to serology, it soon became evident that these antigens are widely distributed in human tissues such as platelets. Immunthrombocytopenia (ITP) is a common autoimmune disorder characterized by a low platelet count. In our study, we investigated the relationship between ABO and Rhesus (Rh) blood groups and primary ITP. Materials and Methods: A retrospective study was conducted at our center with 304 patients diagnosed with primary ITP and 491 blood donors. Results: ABO phenotype in patients group A, B, O, AB were 42.8%, 14,1%, 34,9% , 8.2%, respectively and 51,6%, 8,1%, 27,9%, 12,4% in the control group, respectively. Rh phenotype in patients group positive or negative 87,5%, 12,5 % respectively and 88,8%, 11,2% in the control group, respectively. A total of 304 patients with primary ITP, consisting of 203 (66,8%) females, and 101(33,2%) males were included in this study. The mean age was 49,5 ±18 years. There was no significant difference in the distribution of ABO blood types and Rh factor by gender (respectively p=0.176, p= 0.195). Conclusion: In our study, no significant difference was found between the blood group distribution in the population and the blood group distribution of patients diagnosed with primary ITP.

show abstract

Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Cited by 3 publications

References 21 publications

Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer

Overexpression of GRK3, Promoting Tumor Proliferation, Is Predictive of Poor Prognosis in Colon Cancer

Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma

Relation of Immune Thrombocytopenia and Blood Group: A Retrospective Single Center Study

Contact Info

Product

Resources

About